36th Hemophilia Symposium Hamburg 2005

Epidemiology; Hemophilia Therapy - Management of Bleedings and Inhibitors; Orthopedic Treatment in Hemophiliacs; Hemostaseologic Diagnosis; Pediatric Hemostaseology; Free Lectures

Herausgegeben: Scharrer, Inge; Schramm, Wolfgang;Mitarbeit: Auerswald, G.; Kurth, A.; Oldenburg, J.; Schramm, W.; Zieger, B.
Versandkostenfrei!
Versandfertig in 6-10 Tagen
112,99 €
inkl. MwSt.
Weitere Ausgaben:
PAYBACK Punkte
56 °P sammeln!
About 31% of the patients with a factor VIII replacement therapy develop a factor VIII inhibitor.From these are 23% low-responder ( 5BE) [8].In the case of severe hemophilia B,about 10.5% of the patients develop inhibitory antibodies [9]. Anti-factor VIII-antibodies are also seen in 15 78% healthy people without hemophilia [7, 17, 19]. Lacroix-Desmazes et al. [10, 11] showed anti-idiotypic antibodies neutralizing the inhibitory activity of the an- factor VIII antibodies in healthy people. Well-known predisposing factors for inhibitor formation are genetic features of factor VIII,which include ...